Pancreas Transplantation From Donors After Circulatory Death From the United Kingdom

Oxford Transplant Centre, Churchill Hospital, Roosevelt Drive, Oxford, UK.
American Journal of Transplantation (Impact Factor: 6.19). 08/2012; 12(8):2150-6. DOI: 10.1111/j.1600-6143.2012.04075.x
Source: PubMed

ABSTRACT This study reports the comparative short-term results of pancreas transplantation from donors after circulatory death (DCD) (Maastricht III & IV), and pancreases from brainstem deceased donors (DBD). Between January 2006 and December 2010, 1009 pancreas transplants were performed in the United Kingdom, with 134 grafts from DCD and 875 from DBD. DCD grafts had no premortem pharmacological interventions performed. One-year pancreas and patient survival was similar between DCD and DBD, with pancreas graft survival significantly better in the DCD cohort if performed as an SPK. Early graft loss due to thrombosis (8% vs. 4%) was mainly responsible for early graft loss in the DCD cohort. These results from donors with broader acceptance criteria in age, body mass index, premortem interventions, etc. suggest that DCD pancreas grafts may have a larger application potential than previously recognized.

Download full-text


Available from: Anand Muthusamy, Jan 13, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Of all vascularized organ transplant procedures, pancreas transplantation is plagued with the highest incidence of so-called « technical » complications, often resulting in early graft loss. Up to 10% of pancreas grafts are lost from non-immunologic causes within the first 3 months after transplantation, the most dreaded being graft thrombosis (1). Elucidating the risk factors for technical failure, and preventing its occurrence has been a major endeavor for all pancreas transplant teams over the past decades. Ischemia-reperfusion injury is a key mechanism of technical complications and can be mitigated by decreasing preservation time. Other factors have long been identified for their impact on immediate technical complications. The most critical are donor-related, namely donor older age and overweight/obesity (2,3). This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
    Transplant International 04/2015; DOI:10.1111/tri.12599 · 3.16 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pancreas transplantation is an accepted treatment for a subset of patients with diabetes mellitus, in particular those with renal failure who also require a kidney transplant and those with life-threatening hypoglycaemic unawareness. As results have improved and demand has risen, attention has focused on increasing the availability of pancreas transplantation by utilising pancreases from less than ideal donors, as well as addressing factors that limit the longevity of graft survival. The development of islet transplantation has posed additional demands on donor pancreas availability, as well as posing new challenges for donor organ allocation. This review focuses upon some of the current areas of interest in pancreatic transplantation. Copyright © 2015. Published by Elsevier Ltd.
    Pharmacological Research 02/2015; DOI:10.1016/j.phrs.2015.01.005 · 3.98 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: An overview of 30 years of pancreas transplantation at a high volume center. Analysis of patient survival- and graft survival-associated risk factors. All pancreas transplantations performed in our center from January 1, 1984, till December 31, 2012, were evaluated. Covariates influencing pancreas graft survival were analyzed using both univariate and multivariate analysis and Kaplan-Meier analysis. In the study period, 349 pancreas transplantations were performed. With the introduction of modern induction therapy in 1999, 5-year patient survival improved to 92.0% (P = 0.003). Five-year pancreas graft survival improved to 80.3% (P = 0.026). Pancreas graft survival was influenced by left or right donor kidney, transplant type, local origin of procurement team, pancreas cold ischemia time, recipient cerebrovascular disease. Pancreas donor risk index increased to 1.39 over the years and pancreas donor risk index 1.24 or higher is a risk factor for graft survival (P = 0.007). This study has shown excellent results in patient and pancreas graft survivals after 30 years of pancreas transplantation in a high volume center. Different donor, transplant, and recipient related risk factors influence pancreas graft survival. Even with higher risk pancreas donors, good results can be achieved.
    Transplantation 02/2015; DOI:10.1097/TP.0000000000000604 · 3.78 Impact Factor